Farmas USA

Steven Rosenman
"No BS on this call, you can hear JZ's frustration about their depressed stock price. He brought out the heavy guns, science guy, attorney, pretty heavy crew he was rolling with on this CC and they did a nice job.

Clear tier 2 progress and SG&A cost management. Also, way too early in launch to track revenues. Also, promo efforts and early reporting make it foggy. So, focus on scripts, not revs now.

Anchor clear value driver, it will get approved. When it does, my read from the CC is JZ will have higher offers than he does now to consider. AMRN will be sold to highest bidder.

Reiterate $28-32, NCE and Anchor approval."

Que habéis hecho con las vnda?pueden estar muy aburridas rondando esos 11.1x durante un tiempo, no?

En cuanto termine la dilucion que te apuestas a que se desploma...
Me espero a la prox semana

VNDA

Aguanto por ver que pasa, pero hasta la dilución no creo que se mueva de ahí, y son garantías bloqueadas.Se podría cerrar ahora, recoger unos pequeños profits , usar esas garantías para otras operaciones durante unos dias y volver a abrir cortos más tarde

MACK

Buscando el martillo pilón. He promierdado y tengo la media a 4.36. A esta le sacamos unos duros seguro. Aunque los q prepararon el show de ayer le van a sacar unos cuantos mas

VNDA

Meneándose.

11,06 Ya pierde aceite .. La prox semana habra sangre de la buena ...
VNDA

Quería haceros una pregunta en cuanto a SNTA...
He visto una new según la cual, mañana presentan resultados del GALAXY-I....
Estos resultados son los mismos que presentaron en ASCO o son resultados nuevos?

Un saludo

LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 7, 2013-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that the results from an interim survival analysis of the GALAXY-1 trial will be presented at this year’s Best of ASCO Meetings in Chicago, Los Angeles, and Boston. GALAXY-1 is a global, randomized Phase 2b/3 study designed to evaluate the efficacy and safety of the Company’s lead drug candidate, ganetespib, as second-line treatment for patients with advanced non-small cell lung adenocarcinoma.

The recent interim analysis for overall survival in GALAXY-1 was first presented on June 3 during an oral session at the 2013 ASCO Annual Meeting in Chicago by Dr. Suresh Ramalingam, M.D., Professor, Hematology & Medical Oncology, and Director, Division of Medical Oncology, of the Winship Cancer Institute of Emory University. Results showed the combination of ganetespib and docetaxel improved overall survival and progression-free survival compared to docetaxel alone, and confirmed earlier findings of enhanced clinical activity in the prospectively specified patient population selected last year for further evaluation in the GALAXY-2 Phase 3 trial. GALAXY-2 is currently enrolling patients, with results expected in 2014.

The GALAXY-1 results will be presented during the “Non-small Cell Metastatic Lung Cancer” sessions taking place at:

Best of ASCO Chicago
August 10, 2013, 10:00 – 11:00 AM CDT

Best of ASCO Los Angeles
August 17, 2013, 10:00 – 11:00 AM PDT

Best of ASCO Boston
August 24, 2013, 10:00 – 11:00 AM EDT

Slides discussing the GALAXY-1 results presented at ASCO are available on the Company’s website at www.syntapharma.com.

SNTA